BiotechTube

ENZ215 + EU Sourced Prolia + US Sourced Prolia

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy Male Subjects

Conditions

Healthy Male Subjects

Trial Timeline

Jan 10, 2022 → May 22, 2024

NCT ID
NCT05245669

About ENZ215 + EU Sourced Prolia + US Sourced Prolia

ENZ215 + EU Sourced Prolia + US Sourced Prolia is a phase 1 stage product being developed by Alkem Laboratories for Healthy Male Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT05245669. Target conditions include Healthy Male Subjects.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05245669Phase 1Completed

Competing Products

20 competing products in Healthy Male Subjects

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
33
ValsartanNovartisPhase 1
33
CSL112 + PlaceboCSLPhase 1
32
UT-15CUnited TherapeuticsPhase 1
30
VNA-318 + PlaceboBiotrialPhase 1
25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
25
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
25
Radiolabeled TRV130TrevenaPhase 1
25
TRV130A + Dextrose in WaterTrevenaPhase 1
25
TRV734TrevenaPhase 1
25
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
33
KPL-404Kiniksa PharmaceuticalsPhase 1
28
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
33
Propranolol + PseudoephedrineEli LillyPre-clinical
23
LY2157299Eli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 1
33
LY3015014 + PlaceboEli LillyPhase 1
33
LOXO-783Eli LillyPhase 1
33
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
33
LY3867070 + PlaceboEli LillyPhase 1
33

Other Products from Alkem Laboratories

ENZ215 + ProliaPhase 3
77
BSG005Phase 1/2
41